- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07938931
Low Tidal Volume Strategy In Cardiogenic Pulmonary Edema: The Logical Trial (LOGICAL)
Some people with heart failure develop fluid buildup in the lungs and need a breathing machine while they are treated in an intensive care unit. The amount of air delivered with each breath may affect how quickly they recover.
The LOGICAL study will compare two ways of setting the breathing machine: delivering a lower or an intermediate amount of air with each breath. About 300 adults in intensive care units across Spain will be randomly assigned to one of these strategies.
The study aims to find out whether the lower amount of air increases the number of days patients are alive and breathing without the machine during the first 28 days after assignment. The researchers will also assess other outcomes, including survival and length of stay in the intensive care unit and hospital.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Dr Laura Amado-Rodríguez
- Número de teléfono: +34 985108000
- Correo electrónico: laura.amado@sespa.es
Copia de seguridad de contactos de estudio
- Nombre: Dr Miguel Ángel Rodríguez Yago
- Número de teléfono: +34 985108000
- Correo electrónico: miguelangel.rodriguezyago@gmail.com
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Admission to a participating intensive care unit (ICU).
-
Within the first 24 hours of invasive mechanical ventilation, whether ventilation was started before or after admission to the participating ICU.
-
Expected duration of invasive mechanical ventilation greater than 24 hours.
-
Acute hypoxemic respiratory failure of cardiogenic origin, meeting all three of the following criteria:
-
PaO2/FiO2 ratio below 300 mmHg.
-
Pulmonary congestion shown by at least one of the following:
- Lung ultrasound showing multiple B-lines (at least 3 per zone), distributed bilaterally in at least 2 zones per hemithorax; or
- Chest radiograph showing interstitial or alveolar edema, vascular redistribution, or Kerley B-lines.
-
Evidence of a cardiogenic origin shown by at least one of the following:
- Echocardiographic evidence of elevated left-sided filling pressures (E/e' >14 or E/A >2); or
- Pulmonary capillary wedge pressure >15 mmHg measured with a pulmonary artery catheter.
-
Exclusion Criteria:
- Participation in another interventional clinical trial.
- More than 24 hours of invasive mechanical ventilation.
- Extracorporeal support already initiated.
- Expected extubation within the next 24 hours.
- A predominantly noncardiogenic cause of acute respiratory failure, including acute respiratory distress syndrome, active pneumonia or other pulmonary infection, confirmed pulmonary embolism, or acute lung injury of noncardiac origin.
- Pregnancy.
- Risk of or suspected elevated intracranial pressure.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage IV chronic obstructive pulmonary disease.
- Known pre-existing interstitial lung disease.
- Previous pneumonectomy or lobectomy.
- Terminal condition, a decision to limit life-sustaining treatment, or a do-not-resuscitate order.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Low Tidal Volume Ventilation
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 ml/kg of predicted body weight. Tidal volume may be reduced to 4 ml/kg according to respiratory mechanics and clinical tolerance. |
Volume-controlled invasive mechanical ventilation with an initial tidal volume of no more than 6 mL/kg of predicted body weight. Tidal volume may be reduced stepwise to 4 mL/kg according to respiratory mechanics and clinical tolerance. |
|
Comparador activo: Intermediate Tidal Volume Ventilation
Participants will receive volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining airway pressures within the protocol-defined safety limits. |
Volume-controlled invasive mechanical ventilation with an initial tidal volume of at least 8 mL/kg of predicted body weight. Tidal volume may be adjusted up to 10 mL/kg while maintaining plateau pressure below 30 cmH₂O and driving pressure below 15 cmH₂O. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Days Alive and Free of Invasive Mechanical Ventilation Through Day 28
Periodo de tiempo: From randomization through day 28
|
Number of days from randomization through day 28 that a participant is alive and free of invasive mechanical ventilation. Participants who die before day 28 are assigned 0 days. Higher values indicate a more favorable outcome. |
From randomization through day 28
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
All-Cause Mortality at Day 28
Periodo de tiempo: From randomization through day 28
|
Percentage of participants who die from any cause within 28 days after randomization. |
From randomization through day 28
|
|
Duration of Invasive Mechanical Ventilation
Periodo de tiempo: From randomization until successful liberation, death, or day 90
|
Time from randomization to successful liberation from invasive mechanical ventilation, defined as remaining free of invasive mechanical ventilation for at least 48 hours. Death before liberation will be considered a competing event in the analysis. |
From randomization until successful liberation, death, or day 90
|
Colaboradores e Investigadores
Investigadores
- Investigador principal: Laura Amado-Rodríguez, MD, PhD, Hospital Universitario Central de Asturias
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- LOGICAL Trial
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The investigators intend to explore sharing anonymized individual participant data after publication of the main results, subject to ethical approval, applicable data protection requirements, and assessment of re-identification risk. The specific data sets, access process, and availability period have not yet been determined.
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .